Group 1 - The core point of the announcement is that Shanghai Pharmaceuticals has received a drug registration certificate from the Philippines Food and Drug Administration for its Pregabalin capsules, allowing the product to be marketed in the Philippines [1][4]. Group 2 - The drug is named Pregabalin capsules, available in dosages of 50mg, 75mg, and 150mg, and is classified as a chemical generic drug [1]. - Pregabalin capsules are primarily used for treating postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1]. Group 3 - The development of Pregabalin capsules was completed by Changzhou Pharmaceutical Factory in October 2019, and the product received FDA approval in the United States in July 2021. It also obtained drug registration certificates in Thailand in June 2025 and Singapore in January 2026 [2]. Group 4 - As of the end of 2024, there are 19 distributors of Pregabalin capsules in the Philippines, including UNILAB, VIATRIS INC, and NATRAPHARM. The total sales amount for the three dosages in the Philippines market is projected to be $13.37 million [3].

Regulatory Updates - In 2025, the National Medical Products Administration (NMPA) received 457 special approval applications for innovative medical devices, with 104 approved for special review and 38 priority applications, of which 26 were granted priority approval [1] - By the end of 2025, 475 traditional Chinese medicine production bases passed inspections, covering nearly 1.24 million acres and providing 101 types of Chinese medicinal materials for 215 production enterprises [2] Company Announcements - Shanghai Pharmaceuticals announced that its pregabalin capsules received a drug registration certificate from the Philippines, with a total sales amount of $13.37 million for three specifications [2] - Jiukang Bio received a medical device registration certificate for its albumin assay kit, valid until February 12, 2031 [3] Clinical Research - Eli Lilly's orforglipron demonstrated superior efficacy in glycemic control and weight loss compared to oral semaglutide in a head-to-head study involving 1,698 participants [4][5] - The study results were published in The Lancet, indicating significant improvements in A1C and weight reduction with orforglipron [5] Financial Performance - Baili Tianheng reported a net loss of 1.051 billion yuan for 2025, a significant decline from the previous year, with total revenue of 2.520 billion yuan, down 56.72% [8] - Junshi Biosciences achieved a total revenue of 2.498 billion yuan in 2025, a year-on-year increase of 28.23%, but reported a net loss of 874 million yuan [8] - Yifang Bio reported a net loss of 317 million yuan for 2025, with total revenue of 37.3253 million yuan, down 77.89% [9] - Nanmo Bio's total revenue for 2025 was 421.2586 million yuan, up 10.50%, with a net profit increase of 399.29% to 32.4313 million yuan [10]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Philippines Food and Drug Administration for the marketing of its pregabalin capsules, indicating a significant milestone for the company in expanding its product offerings in international markets [1] Group 1 - The company announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has successfully obtained a drug registration certificate for pregabalin capsules [1] - The approval marks a key step in the company's strategy to enhance its presence in the pharmaceutical market of the Philippines [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Philippines Food and Drug Administration for its Pregabalin capsules, allowing the product to be marketed [1] Group 1: Product Approval and Indications - Pregabalin capsules are primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1] - The product development for Pregabalin capsules was completed by Changzhou Pharmaceutical Factory in October 2019 [1] Group 2: Regulatory Approvals Timeline - The Pregabalin capsules received approval from the U.S. Food and Drug Administration in July 2021 [1] - The product obtained a drug registration certificate in Thailand in June 2025 and in Singapore in January 2026 [1] Group 3: Investment in R&D - The company has invested approximately RMB 2.19 million in research and development for the product's market entry in Southeast Asia, which includes Thailand, Singapore, Malaysia, and the Philippines [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) has received approval from the Philippines Food and Drug Administration for the marketing of Pregabalin capsules produced by its subsidiary, Changzhou Pharmaceutical Factory [1] Group 1: Product Approval - The Pregabalin capsules are primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, and neuropathic pain due to spinal cord injury, as well as for adjunctive treatment of epilepsy [1]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, has received a drug registration certificate from the Philippines Food and Drug Administration for the launch of Pregabalin capsules, which are approved for sale in three specifications: 50mg, 75mg, and 150mg. This approval is expected to positively impact the company's expansion into overseas markets, although there are various uncertainties that may affect sales performance [1]. Group 1 - The drug Pregabalin is primarily used for the treatment of neuropathic pain and as an adjunct therapy for epilepsy [1]. - The total sales for the same specifications of the drug in the Philippines market for 2024 are projected to be $13.37 million [1]. - The company has invested additional research and development expenses for the drug's market entry in Southeast Asia [1].

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Philippines Food and Drug Administration for its Pregabalin capsules, allowing the product to be marketed in the Philippines [1] Group 1: Product Approval and Market Impact - The Pregabalin capsules are primarily used for treating postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1] - The approval marks the company's qualification to sell the drug in the Philippines, which is expected to positively impact the company's expansion into overseas markets and accumulate valuable experience [1] Group 2: Financial and Market Data - The total sales amount for Pregabalin capsules in the Philippines market across three specifications (50mg, 75mg, 150mg) is reported to be $13.37 million [1] - The research and development expenses incurred for launching the product in the Southeast Asian market (including Thailand, Singapore, Malaysia, and the Philippines) amount to approximately RMB 2.19 million [1]

Core Viewpoint - The company announced that its subsidiaries and a holding subsidiary participated in a national procurement program and have proposed to be selected for six pharmaceutical products, with a procurement period extending until December 31, 2028 [1] Group 1: Company Participation - The company’s wholly-owned subsidiaries, including Shaanxi Buchang High-tech Pharmaceutical Co., Ltd. and Shandong Danhong Pharmaceutical Co., Ltd., along with its holding subsidiary Jilin Tiancheng Pharmaceutical Co., Ltd., are involved in the national organized procurement program [1] - The selected products include Amlodipine Besylate Tablets, Rivaroxaban Tablets, Metoprolol Tartrate Tablets, Lacosamide Tablets, Pregabalin Capsules, and Torasemide Injection [1] Group 2: Procurement Details - The procurement cycle for the selected drugs will commence from the actual execution date of the selection results and will last until December 31, 2028 [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Health Sciences Authority (HSA) of Singapore for its Pregabalin capsules, allowing the product to be marketed [1] Group 1: Product Approval and Indications - Pregabalin capsules are primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1] - The product's research and development were completed by Changzhou Pharmaceutical Factory in October 2019, and it received approval from the U.S. Food and Drug Administration in July 2021 [1] Group 2: Market Expansion and Investment - The drug has also been approved for market entry in Thailand by June 2025, indicating a strategic expansion into Southeast Asian markets [1] - The company has invested approximately RMB 2.19 million in research and development for the product's launch in Southeast Asia, which includes Thailand, Singapore, Malaysia, and the Philippines [1]

Group 1 - Shanghai Pharmaceuticals has received approval for the production of Avatrombopag Maleate Tablets from the National Medical Products Administration [1][2] - The drug is indicated for adult patients with chronic liver disease-related thrombocytopenia undergoing elective diagnostic procedures or surgery, and for adults with chronic primary immune thrombocytopenia (ITP) who have had inadequate responses to previous treatments [3] - The company has invested approximately RMB 9.8961 million in the research and development of this drug as of the announcement date [3] Group 2 - The drug's approval is expected to enhance market share and competitiveness, benefiting from greater support in medical insurance and procurement due to its new registration classification [5] - The total procurement amount for Avatrombopag Maleate Tablets in hospitals in mainland China is projected to be RMB 566.56 million in 2024 [4] Group 3 - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, has received a drug registration certificate for Pregabalin Capsules from the Health Sciences Authority of Singapore, allowing it to market the drug in Singapore [8][9] - Pregabalin Capsules are indicated for the treatment of neuropathic pain and as an adjunct therapy for epilepsy, with a total investment of approximately RMB 2.19 million in R&D for the Southeast Asian market [9] - The sales revenue for Pregabalin Capsules in Singapore is estimated to be USD 2 million in 2024 [11]